bepridil and metoprolol

bepridil has been researched along with metoprolol in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (16.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (66.67)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET	1
Topliss, JG; Yoshida, F	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ	1
Hayano, T; Itagaki, K; Kimura, M; Matsuzaki, M; Ohmura, M; Shimizu, A; Ueyama, T; Yamagata, T; Yoshiga, Y	1

Trials

1 trial(s) available for bepridil and metoprolol

Article	Year
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil. Circulation journal : official journal of the Japanese Circulation Society, 2002, Volume: 66, Issue:11 Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Bisoprolol; Drug Antagonism; Drug Therapy, Combination; Electrocardiography; Female; Heart Conduction System; Humans; Long QT Syndrome; Male; Metoprolol; Middle Aged; Treatment Outcome	2002

Article

Year

Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.

Circulation journal : official journal of the Japanese Circulation Society, 2002, Volume: 66, Issue:11

Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Bisoprolol; Drug Antagonism; Drug Therapy, Combination; Electrocardiography; Female; Heart Conduction System; Humans; Long QT Syndrome; Male; Metoprolol; Middle Aged; Treatment Outcome

2002

Other Studies

5 other study(ies) available for bepridil and metoprolol

Article	Year
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs. Journal of medicinal chemistry, 1985, Volume: 28, Issue:3 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium	1985
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:1 Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity	2013